NCT02977442Completed
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise
Dynamics of Muscle Mitochondria in Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 29 Apr 2025
Brief summary (registry, in English)
Insulin promotes the clearance of sugars from the blood into skeletal muscle and fat cells for use as energy; it also promotes storage of excess nutrients as fat. Type 2 diabetes occurs when the cells of the body become resistant to the effects of insulin, and this causes high blood sugar and contributes to a build-up of fat in muscle, pancreas, liver, and the heart. Understanding how insulin resistance occurs will pave the way for new therapies aimed at preventing and treating type 2 diabetes. Mitochondria are cellular structures that are responsible for turning nutrients from food, into the energy that our cells run on. As a result, mitochondria are known as "the powerhouse of the cell." Mitochondria are dynamic organelles that can move within a cell to the areas where they are needed, and can fuse together to form large, string-like, tubular networks or divide into small spherical structures. The name of this process is "mitochondrial dynamics" and the process keeps the cells healthy. However, when more food is consumed compared to the amount of energy burned, mitochondria may become overloaded and dysfunctional resulting in a leak of partially metabolized nutrients that can interfere with the ability of insulin to communicate within the cell. This may be a way for the cells to prevent further uptake of nutrients until the current supply has been exhausted. However, long term overload of the mitochondria may cause blood sugar levels to rise and lead to the development of type 2 diabetes. This study will provide information about the relationship between mitochondrial dynamics, insulin resistance and type 2 diabetes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 28 Nov 2016
- Start date
- Nov 2016
- Primary completion date
- Sept 2023
- Lead sponsor
- Pennington Biomedical Research Center
- Diseases
- Type 2 diabetes
- NCT number
- NCT02977442
What you commit to
- Study type: Interventional
- Participants enrolled: 24
- From Nov 2016 to the primary completion date, Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Evidence of type 1 diabetes or requiring insulin therapy
Other
- BMI \>50 kg/m2
- Smoking
- Active pregnancy
Who the study is looking for
- Type 2 Diabetes
- Body Mass Index (BMI) between 25 and 50 kg/m2
- HbA1C \< 10%
- Sedentary
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pennington Biomedical Research Center Coordinator of this site? Confirm its status | Baton Rouge | United States | Unknown status |
Related publications
- Miro1 mediates skeletal muscle insulin resistance in type 2 diabetes.Nat Commun · 2026 · PMID 42897135
This page is information, not medical advice. Discuss any trial with your doctor.